Peptide Decoding
New?New to peptides?Start here →
Decoding

Tetrapeptide-30 (PKEK)_Dosage, benefits & legal status

Also known as PKEK, Pro-Lys-Glu-Lys, H-Pro-Lys-Glu-Lys-OH, TEGO Pep 4-Even

Published November 17, 2026

A brightening peptide with real controlled data, tested at 40 parts per million.

Pigment & dark spotsCosmetic tetrapeptide (topical)Cosmetic
DoseSet by the finished product
FrequencyDaily, as directed by the product
RouteOn the skin (topical)
StatusCosmetic ingredient
CycledNot cycled

See how this dose compares across the library →

01

What is Tetrapeptide-30 (PKEK)?

Plain language first. The technical label stays, but it never stands alone.

Overview

It calms the signals that tell skin to make pigment, so fewer new dark spots form.

The technical version

Tetrapeptide-30 is a cosmetic tetrapeptide that suppresses UVB-induced transcription of proopiomelanocortin and inflammatory cytokines in keratinocytes, reducing melanocyte activation and tyrosinase.

What it's used for

A topical peptide for uneven tone and dark spots that acts on the signals behind pigment rather than on pigment itself.

02

How does Tetrapeptide-30 (PKEK) work?

What it does in the body, and where.

Tetrapeptide-30 is proline, lysine, glutamic acid, lysine. It does not touch melanin. It works a step earlier, on the inflammatory signals that drive skin to make pigment in the first place.

  1. 01
    UVB makes keratinocytes shout at melanocytes
    Ultraviolet light drives skin cells to transcribe proopiomelanocortin, the gene behind the hormone that switches pigment cells on, along with the inflammatory messengers interleukin-6, interleukin-8 and TNF-alpha.
  2. 02
    The peptide quiets that transcription
    In human keratinocytes, PKEK significantly reduced UVB-stimulated messenger RNA for all four. In a skin biopsy study at 40 parts per million, the same four plus tyrosinase and COX-2 came down against a vehicle control.
  3. 03
    Less signal reaching the pigment cells
    The manufacturer's reading is that the anti-inflammatory effect lowers the amount of tyrosinase and holds melanocytes back from activating, and that the peptide alters how keratinocytes and melanocytes talk to each other.
  4. 04
    What this means for what you should expect
    An ingredient that works on new pigment formation is not a bleaching agent. It has nothing to remove what is already in the skin, which is why the studies run 6 to 12 weeks and report fading rather than clearing.
Pathway
THE PEPTIDE
Tetrapeptide-30 (PKEK)
ACTS ON
Keratinocyte signaling to melanocytes
RESULT
Less UVB-driven POMC, tyrosinase, COX-2, TNF-alpha, IL-6 and IL-8
RESULT
Less melanocyte activation, so less new pigment

A schematic of the compound's mechanism, not a diagnostic image.

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Evening out skin tone and fading age spots, applied to the skinpeer-reviewed-human
  • Reducing acne lesions, which the supplier claims and its own technical sheet does not quantifynone
  • Alleviating melasma, which the supplier claims and its own technical sheet describes no study fornone

The published record

Research index

15

Papers about Tetrapeptide-30 (PKEK) · this compound only

Searched: Tetrapeptide-30, PKEK, Pro-Lys-Glu-Lys, TEGO Pep 4-Even, 1036207-61-0.

4 papers tagged human · 3 not reviews or lab · 2 clinical trial publications

How the compound was given: 6 applied to skin · 1 injected · 8 route not stated in the abstract

Read from each paper's indexing terms and abstract, by rule. A paper that mentions a cream studied a cream, not necessarily the product being sold.

Furthest stage reached: Published trials only, 2 clinical trial publications, no phased trial registered

Compare this against the whole library →

In animals9
In the lab5
Reviews1
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once. 15 papers and 0 trials held here.

Tetrapeptide-30 (PKEK) vial rendering
Compound field notes

At a glance

Four things to know about Tetrapeptide-30 (PKEK)

01

Evidence

Cosmetic

02

Category

Skin and cosmetic

03

Common vial

Varies

04

Half-life

Not measured, and not the right question

04

How much, and do you cycle it?

The range, and whether you take breaks.

Set by the finished product, daily, as directed by the product. Not cycled Community practice

Used daily as part of a routine. Pigment returns when ultraviolet exposure continues and the signal it suppresses resumes, so there is nothing to cycle off.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not measured, and not the right questionNo figure

This is a topical cosmetic ingredient and no half-life has been published for it. A blood half-life measures how fast something leaves the bloodstream, and this is not intended to reach it. What matters for a topical is how much crosses the stratum corneum and how long it stays in the tissue. That has at least been studied for this peptide: it is highly water-loving, which normally works against skin penetration, and a published delivery study examined carrier systems to get it through.

You can compare this against the whole library to see where it sits.

06

How is it given?

Dosing context and source notes.
No draw available

Supplied as a ready-made solution, so there is nothing to mix.

Reported range: 0.001 up to 0.008 % per formulation. Evonik, TEGO Pep 4-Even technical information, March 2011

These percentages are the peptide itself, worked out from the supplier's own two numbers so you can check them. The trade solution is about 1600 parts per million of peptide in glycerin and water, and the recommended use level is 0.5 to 5.0 percent of that solution, which puts the peptide between 0.0008 and 0.008 percent of a finished product. The supplier says it was clinically tested at a 2.5 percent use level, which works out to 40 parts per million, or 0.004 percent, and 40 parts per million is exactly the concentration the skin biopsy study used. Those two figures agreeing is the reason to trust the arithmetic. A product that tells you it contains the trade solution at 2 percent is telling you about the solution, not the peptide.

07

How do you store it?

Before mixing, and after.

Room temperature, out of light. Cap it tight after each use.

Tetrapeptide-30 (PKEK) ships as a cream, gel, or serum. Keep it at room temperature away from sun and heat unless the label says otherwise. Refrigerating an emulsion can split the texture. Watch for color, smell, or separation changes and stop using it if any appear.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • A known allergy to this ingredient or to others in the same product
  • Broken, cracked, or actively irritated skin

Stop and get help

These are emergencies. Seek care.
  • A rash that spreads beyond where you applied it
  • Swelling of the face, lips, or eyelids, or any trouble breathing
  • Burning that does not settle after rinsing it off

Common effects

Expected, and usually mild.
  • No adverse effects are described in the manufacturer's technical information or in the published studies, though neither reports a safety tally. Irritation from a product containing it may come from anything else in the formula.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is Tetrapeptide-30 (PKEK) approved?

And where the numbers on this page come from.

Not as a medicine. Tetrapeptide-30 (PKEK) is sold without a prescription as a cosmetic ingredient, which is a different thing from being approved as a drug.

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

Guides for this compound

Sources

  • Evonik, TEGO Pep 4-Even technical information, March 2011(2011)
    The manufacturer's own technical information, read at source, and the most useful document on this peptide precisely because it undercuts the marketing above it. It gives the composition as a preservative-free solution of Tetrapeptide-30 in glycerin and water at about 1600 parts per million, a recommended use level of 0.5 to 5.0 percent, and clinical testing at 2.5 percent. It then describes five studies and states a volunteer count for none of them. Only one carries a number: in Asian skin over 8 weeks, the peptide with sodium ascorbyl phosphate gave about a 15 percent reduction in hyperpigmentation against a vehicle containing the vitamin C salt alone, which had no change. The skin biopsy study used 40 parts per million against a vehicle, both under 1.5 minimal erythema doses of UVB, and reported reduced gene expression of proopiomelanocortin, tyrosinase, COX-2, TNF-alpha, interleukin-6 and interleukin-8 with significance marks but no percentages. Three of the five studies combine the peptide with the vitamin C salt. The benefit list claims melasma relief and fewer acne lesions; no melasma study is described.
  • Marini et al., Modulation of skin pigmentation by the tetrapeptide PKEK: in vitro and in vivo evidence for skin whitening effects, Experimental Dermatology 21(2):140-146(2012)
    The peer-reviewed study behind the ingredient, and the reason this peptide sits above most cosmetic peptides on evidence. Thirteen authors led from the IUF Leibniz Research Institute for Environmental Medicine in Dusseldorf, with three of the ingredient maker's scientists among them, reporting skin whitening effects from one in vitro and four double-blinded vehicle-controlled in vivo studies. The in vitro arm is the clean part: treating human keratinocytes with PKEK significantly reduced UVB-stimulated messenger RNA for interleukin-6, interleukin-8, TNF-alpha and, the authors emphasize, proopiomelanocortin. Indexed as a clinical trial in MEDLINE. The abstract was read through the publisher's listing; the full text was not opened here.
  • Evonik, TEGO Pep 4-Even MB product page(2026)
    The manufacturer's current product page, which is the marketing claim set to compare against the technical sheet above. It claims the peptide visibly diminishes hyperchromatic spots, brightens skin and improves evenness of tone, alleviates melasma on ethnic skin, safely inhibits the pigmentation process, provides a significant anti-inflammatory effect and reduces acne lesions.
  • United States patent application 20120244094, Tetrapeptides for brightening the skin, Farwick et al.(2012)
    The patent application behind the ingredient, which is where the use claim is staked rather than demonstrated. Filed by the ingredient maker's scientists with German priority, it claims a method of applying PKEK to human skin at least once a day to reduce or eliminate unwanted pigmentation. A claimed method is not evidence that the method works; it is included here so a reader who meets the phrase patent-protected application on a supplier page knows what it refers to.
  • MedChemExpress, Tetrapeptide-30 product data sheet(2026)
    Reagent-supplier reference data, used here only for the molecular identifiers and for the second published reference it names. Gives CAS 1036207-61-0, molecular formula C22H40N6O7, molecular weight 500.59, sequence PKEK, and records that the peptide is highly hydrophilic with good skin penetration in microemulsion, citing a dermal peptide delivery study by Neubert and colleagues in the European Journal of Pharmaceutics and Biopharmaceutics. That delivery paper was not opened at source here.

Beyond these, 15 records are indexed for this compound. Browse the records